Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Total Liabilities (2021 - 2026)

TriSalus Life Sciences has reported Total Liabilities over the past 6 years, most recently at $58.2 million for Q1 2026.

  • For Q1 2026, Total Liabilities fell 7.66% year-over-year to $58.2 million; the TTM value through Mar 2026 reached $58.2 million, down 7.66%, while the annual FY2025 figure was $69.2 million, 38.76% up from the prior year.
  • Total Liabilities for Q1 2026 was $58.2 million at TriSalus Life Sciences, down from $69.2 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $69.2 million in Q4 2025 and troughed at $12.0 million in Q2 2022.
  • A 5-year average of $41.2 million and a median of $49.9 million in 2024 define the central range for Total Liabilities.
  • Biggest five-year swings in Total Liabilities: soared 271.65% in 2024 and later dropped 7.66% in 2026.
  • Year by year, Total Liabilities stood at $34.3 million in 2022, then soared by 50.54% to $51.7 million in 2023, then fell by 3.48% to $49.9 million in 2024, then surged by 38.76% to $69.2 million in 2025, then decreased by 15.93% to $58.2 million in 2026.
  • Business Quant data shows Total Liabilities for TLSI at $58.2 million in Q1 2026, $69.2 million in Q4 2025, and $63.2 million in Q3 2025.